Latest Clinical News

Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising (07-11-2017)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking... Continue Reading

First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients (07-6-2017)

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics... Continue Reading

SUNSHINE: Vitamin D Slows Colon Cancer Progression (07-6-2017)

The first-ever completed comparative clinical trial of the use of vitamin D as a colorectal cancer therapy has shown that disease progression is slowed with high-dose supplements according to lead author Kimmie Ng, MD, of the Dana Farber Cancer Institute... Continue Reading

Ovarian Cancer Clinical Trials: What, Where, Why (07-5-2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study (07-5-2017)

Data from an ongoing clinical study of tisotumab vedotin in solid tumors has demonstrated activity in the treatment of cervical cancer; 11 of 34 evaluable patients achieved a response; with a median time of treatment of 4.9 months and 7 responders are... Continue Reading

Shorter Duration Chemotherapy Possible for Early Stage Colon Cancer (06-26-2017)

Many colon cancer patients can cut their chemotherapy regimen in half, improving their quality of life and reducing their chances of having debilitating side effects, according to the results of a major study released at the American Society of Clinical... Continue Reading

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation (06-26-2017)

The U.S. Food and Drug Administration granted regular approvals to Tafinlar® (dabrafenib) and Mekinist® (trametinib) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by... Continue Reading

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer (06-22-2017)

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple... Continue Reading

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia (06-20-2017)

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML is the most lethal of the blood cancers,... Continue Reading

FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma (06-19-2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy. ... Continue Reading

With Nearly Three Years of Follow-Up, Keytruda® Continues to have Improved Survival Benefit Compared to Yervoy® in Advanced Melanoma (06-15-2017)

Keytruda® (pembrolizumab) continues to outperform Yervoy® (ipilimumab) as initial treatment of patients with advanced melanoma. Updated results of the KEYNOTE 006 trial presented at the 2017 annual meeting of the American Society of Clinical Oncology... Continue Reading

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia (06-14-2017)

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended the lives of patients... Continue Reading

Next Page »